XIIPlate XIIReviewed 2026-04-25

KPV

Tripeptide (Lys-Pro-Val)

also known as Lys-Pro-Val, alpha-MSH 11-13

Tripeptide (Lys-Pro-Val) corresponding to the C-terminus of α-melanocyte- stimulating hormone (α-MSH). Retains the anti-inflammatory and immune- modulatory properties of full α-MSH without the pigmentation effects. Multiple animal studies support efficacy in inflammatory bowel disease, acne, and atopic dermatitis. Often paired orally / topically with BPC-157 for gut and skin protocols.

§ I

At a glance

Daily dose

200–500 mcg

[dalle-pang-2024]

Evidence level

Animal

[dalle-pang-2024]

Half-life (est)

Hours

Route

SQ / oral / topical · Local · Daily or 2-3×/week

§ II

Mechanism

Primary target — Intracellular targets bypassing melanocortin receptors (proposed) [dalle-pang-2024].

Pathway — NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammation [dalle-pang-2024].

Downstream effect — Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protection [dalle-pang-2024].

Origin — Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13) [dalle-pang-2024].

Feedback intact — No melanocortin receptor binding.

§ III

Dosage

Protocols described in the cited literature; not medical advice.

Parameter	Value
Standard dose	200–500 mcg / day SQ or oral [dalle-pang-2024]
Frequency	Daily or 2–3× per week
Lower / starter dose	100 mcg / day
Evidence basis	Animal-strong + emerging clinical data in IBD [dalle-pang-2024]
Duration	4–8 weeks per cycle
Reconstitution	Bacteriostatic water (SQ form)
Timing	No specific time; often taken with / before meals (oral)
Half-life	Hours (estimated; rapid tissue uptake)

§ III · b

Reconstitution

A pure mass-to-volume utility. Enter what you have in the vial; the atlas computes the volume per dose. No prescription information.

Inputs

Lyophilized peptide in vial

Bacteriostatic water added

Desired dose

mcg

The calculator does pure mass-to-volume math. It does not recommend a dose. Refer to KPV's cited literature for protocol specifics.

Volumetric outputFig. C — reconstitution math

Volume per dose

0.100mL

≈ 10.0 units on a U-100 insulin syringe

Concentration

2500

mcg per mL

Doses per vial

at this dose

§ V

Adverse events

Severities follow the FDA / CTCAE convention.

Injection site reactionmild

Mild irritation

GI symptomsmild

Rare nausea (oral form)

Pigmentationmild

None (unlike full α-MSH) [dalle-pang-2024]

Long-term safetymoderate

Limited human data

Pregnancy / OBsevere

Avoid — insufficient data

Absolute contraindications

— Pregnancy / breastfeeding

Relative contraindications

— Active autoimmune disease (theoretical)

§ VI

Administration

01
Reconstitution
Add 1 mL bacteriostatic water to vial per labelling.
02
Form
SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.
03
Timing
Morning preferred; oral form taken with / before meals.
04
Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
05
Needle
29–31G insulin syringe (SQ form).

§ VII

Synergies

strong synergy

KPV + BPC-157

KPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.

Primary benefit — Combined anti-inflammation + mucosal repair for gut conditions

Appendix

Sources

33%

of 39 rendered claims carry a resolvable citation.

[dalle-pang-2024]
Dalle-Pang 2024 — KPV peptide as an anti-inflammatory and gut-barrier protective agent
Inflamm Bowel Dis, 2024
Source →
[sikiric-2018]
Sikiric 2018 — Stable gastric pentadecapeptide BPC 157, an effective anti-inflammatory agent: a comprehensive review
Curr Pharm Des, 2018
PubMed →

Plate composed 2026-04-25 · maturity draft · schema v1 · Contributors: peptidesdb-core · 26 fields uncited — open contributions

Edit on GitHub →Read another →